Gordon Fox • October 28, 2022
Expert consensus on syncope in HCM

An expert panel of HCM clinicians and researchers has published ( Brignole et al. 2022 ) a set of guidelines for diagnosing the causes of syncope (fainting) in HCM patients, and for treatment if indicated.

Fainting is fairly common among HCM patients (about 15%, Mascia et al. 2022 ), but its causes are usually unknown. Indeed, it is often assumed to be caused by arrhythmias, and used to make decisions about implanting ICDs. As there are many other things that can cause syncope, though, this can lead to inappropriate ICD implantation, as well as to failing to understand and treat the real cause of the syncope.

Causes of syncope

Most syncope (about 91%) among HCM patients appears to be unexplained, according to an earlier meta-analysis by the same panel ( Mascia et al. 2022 ). In addition to ventricular arrhythmias that can be prevented or aborted by ICDs, there are many other cardiac causes of fainting. There are also multiple causes of syncope that are neural in origin, as well as conditions that mimic syncope. Distinguishing among these is quite valuable clinically.

The recommended workup for HCM patients with syncope is

The guidelines are published in the International Journal of Cardiology.

Recommended workup for HCM patients with syncope.

Literature cited

Mascia, G., Crotti, L., Groppelli, A., Canepa, M., Merlo Andrea, C., Benenati, S., et al. Syncope in hypertrophic cardiomyopathy (part I): an updated systematic review and meta-analysis. 2022. Int. J. Cardiol., S973-983-7429, 10.1016/j.ijcard.2022.03.028

Brignole, M., Cecchi, F., Anastasakis, A., Crotti, L., Deharo, J.C., Elliott, P.M., Fedorowski, A., Kaski, J.P., Limongelli, G., Maron, M.S. and Olivotto, I., 2022. Syncope in hypertrophic cardiomyopathy (part II): An expert consensus statement on the diagnosis and management. International Journal of Cardiology. 10.1016/j.ijcard.2022.10.153

HCMA Blog

By Erica Friedman June 26, 2025
Investigative journalists Debbie Cenziper, Megan Rose, Brandon Roberts and Irena Hwang from Pro Publica and NPR have concluded a 14-month long investigation into the quality of generic drugs coming into the United States from overseas. Among the many voices that spoke up for American patients was HCMA Founder and CEO, Lisa Salberg who has felt the effects of low-quality drugs personally. Salberg believes that fixing this problem is something we can do, even in this time, when even health care is highly politicized. Read the key takeaways from ProPublica’s 14-month investigation into the FDA’s oversight of foreign drugmakers in Threat in Your Medicine Cabinet: The FDA’s Gamble on America’s Drugs .
A light blue and dark blue paintbrush stroke intersect to make a stylized
By Erica Friedman June 18, 2025
Alnylam press release on the European Commission approval of AMVUTTRA® (vutrisiran) forwild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication
Light & dark blue brush stroke that intersect create an abstract letter 'a' next to the word Alnylam
By Erica Friedman June 17, 2025
AMVUTTRA® (vutrisiran) has been approved by the U.S. Food and Drug Administration (FDA) to treat ATTR-CM in adults.
More Posts